(2022). Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwac232.
(2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437.
(2022). Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. Atherosclerosis. http://doi.org/10.1016/j.atherosclerosis.2022.07.011.
(2022). Incremental value of risk factor variability for cardiovascular risk prediction in individuals with type 2 diabetes: results from UK primary care electronic health records. Int J Epidemiol. http://doi.org/10.1093/ije/dyac140.
(2022). Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019. Clinicoecon Outcomes Res, 14, 189-203. http://doi.org/10.2147/ceor.s347085.
(2022). Long-Term Cardiovascular Risk and Management of Patients Recorded in Primary Care With Unattributed Chest Pain: An Electronic Health Record Study. J Am Heart Assoc, 11, e023146. http://doi.org/10.1161/jaha.121.023146.
(2022). Use of lifestyle interventions in primary care for individuals with newly diagnosed hypertension, hyperlipidaemia or obesity: a retrospective cohort study. J R Soc Med, 1410768221077381. http://doi.org/10.1177/01410768221077381.
(2022). Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England. Cardiovasc Diabetol, 21, 8. http://doi.org/10.1186/s12933-021-01435-y.